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Abstract
Background: Overactive bladder (OAB) affects the lives of millions of people worldwide and antimuscarinics are the
pharmacological treatment of choice. Meta-analyses of all currently used antimuscarinics for treating OAB found similar
efficacy, making the choice dependent on their adverse event profiles. However, conventional meta-analyses often fail to
quantify and compare adverse events across different drugs, dosages, formulations, and routes of administration. In
addition, the assessment of the broad variety of adverse events is dissatisfying. Our aim was to compare adverse events of
antimuscarinics using a network meta-analytic approach that overcomes shortcomings of conventional analyses.
Methods: Cochrane Incontinence Group Specialized Trials Register, previous systematic reviews, conference abstracts, book
chapters, and reference lists of relevant articles were searched. Eligible studies included randomized controlled trials
comparing at least one antimuscarinic for treating OAB with placebo or with another antimuscarinic, and adverse events as
outcome measures. Two authors independently extracted data. A network meta-analytic approach was applied allowing for
joint assessment of all adverse events of all currently used antimuscarinics while fully maintaining randomization.
Results: 69 trials enrolling 269229 patients were included. Similar overall adverse event profiles were found for darifenacin,
fesoterodine, transdermal oxybutynin, propiverine, solifenacin, tolterodine, and trospium chloride but not for oxybutynin
orally administered when currently used starting dosages were compared.
Conclusions: The proposed generally applicable transparent network meta-analytic approach summarizes adverse events in
an easy to grasp way allowing straightforward benchmarking of antimuscarinics for treating OAB in clinical practice. Most
currently used antimuscarinics seem to be equivalent first choice drugs to start the treatment of OAB except for oral
oxybutynin dosages of $10 mg/d which may have more unfavorable adverse event profiles.
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Introduction
Overactive bladder (OAB) is a widespread chronic illness that
affects the lives of millions of people worldwide at all ages but is
more common in the elderly with a prevalence of up to 31% in
women and 42% in men aged over 75 years [1]. OAB has a major
impact on quality of life, affecting emotional, social, sexual,
occupational, and physical aspects of daily life [2–4], and it is
associated with a greater risk of falls and injuries, including
fractures [5], which may even lead to death. Besides the
debilitating manifestations for patients, OAB also imposes
substantial economic burden as direct annual costs are comparable
to those of other chronic diseases such as dementia and diabetes
mellitus [6].
Non-surgical treatment is the mainstay of therapy for OAB
including lifestyle modifications, behavioral therapy, biofeedback,
bladder training, medication and a combination of these options.
Antimuscarinics are the pharmacological treatment of choice for
OAB. Seven antimuscarincs (darifenacin, fesoterodine, oxybuty-
nin, propiverine, solifenacin, tolterodine, and trospium chloride)
with different dosages, formulations, and routes of administration
are currently used for treating OAB and all have well-established
and similar efficacy (figure S1) shown in systematic reviews [7–13],
so that the selection of the most appropriate depends on their
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adverse event profiles. However, over 30 different adverse events
were described and only a few of them were compared
systematically. Moreover, joint assessment of all reported adverse
events of the currently used antimuscarinics is lacking.
In 2004 [14], the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) working group highlight-
ed the importance to interpret quality of evidence in view of trade-
offs between effect and side effects, or desirable and undesirable
consequences of management strategies. However, conventional
meta-analyses often fail to quantify and compare adverse events
across different drugs, dosages, formulations, and routes of
administration, because summaries usually do not use all available
information on reported comparisons and assessment of the broad
variety of adverse events. This is seen as a major impediment when
examining the trade-offs the GRADE working group is calling for.
Recently, new meta-analytic methods – network meta-analysis –
have become available which allow complete assessments across
different drugs. While these methods gained some popularity in
the assessment of treatment effects, their application in side effect
assessment is novel. In view that all antimuscarinics show similar
efficacy, the assessment of side effects alone suffices to provide the
required information for decision-making and evidence grading.
Therefore, we performed a network meta-analysis summarizing
data from all randomized comparative clinical trials assessing
adverse events of all currently used antimuscarinics. Moreover we
propose a way to aggregate the broad variety of reported adverse
events and finally provide adverse event charts for all assessed
medications and dosages allowing straightforward benchmarking
of antimuscarinics for treating OAB in clinical practice.
Methods
Search strategy and selection criteria
This systematic review was done according to the PRISMA
statement [15]. A review protocol was elaborated, which is
available on file with the authors. To identify randomized
controlled trials of antimuscarinics versus placebo (Figure S2),
we started with the recent Cochrane review by Nabi et al. [10] and
a literature search update from June 2005 to November 2007
kindly provided by the Cochrane Incontinence Review Group
according to their previously published search strategy [10]. Head-
to-head comparative trials without a placebo arm were identified
from the two recent meta-analysis by Chapple et al. [12] and by
Novara et al. [13]. In addition, we searched reference lists and
conference abstracts by hand, checked relevant reviews, book
chapters, and contacted manufacturers and trialists. The search
strategies are available on request.
Two investigators (TMK, DL) independently assessed reports
for eligibility. To be included, studies had to be randomized
controlled trials comparing at least one antimuscarinic for treating
OAB with placebo or with another antimuscarinic. All currently
used antimuscarinics were included, i.e. darifenacin, fesoterodine,
oxybutynin, propiverine, solifenacin, tolterodine, and trospium
chloride. Trials with intravesical antimuscarinic administration,
drugs with less direct antimuscarinic effects (such as smooth muscle
relaxants, flavoxate hydrochloride, calcium channel blockers,
potassium channel openers, beta-adrenoceptor agonists, alpha-
adrenoceptor antagonists, prostaglandin synthetase inhibitors, and
tricyclic antidepressants), and drugs no longer used in clinical
practice (such as emepronium bromide or carrageenate, dicyclo-
mine chloride, penthienate, propantheline bromide, and terodi-
line) were excluded. In the case of multiple publications on the
same patients, the most complete report was chosen for each trial.
Data collection
We extracted data in duplicate (TMK, DL) and a third reviewer
(LMB) resolved any discrepancies if the two reviewers disagreed.
We contacted authors of eligible trials that reported insufficient
data and asked them for additional information (Data S1).
Dichotomous data were abstracted into 262 tables. For contin-
uous data, summary estimates per group (means, changes in
means) with measures of variability (standard deviation [SD], 95%
confidence interval [CI]) as available were extracted.
Outcomemeasures were adverse events. After extraction, adverse
events were classified according to the Common Terminology
Criteria for Adverse Events v3.0 (CTCAE) [16] into 7 categories
(gastrointestinal, ocular/visual, urinary tract related, neurological,
cardiac, respiratory tract related, dermatological adverse events)
and then graded using a visual analogue scale (0=minimum
severity, 10=maximum severity) based on the consensus of 10
independent experts (Table 1). Summarizing different formulations
and routes of administration, antimuscarinics were categorized
based on the daily dose used into the following groups: darifenacin
3.75 mg/d, 7.5 mg/d, 15 mg/d, 30 mg/d; fesoterodine 4 mg/d,
8 mg/d, 12 mg/d; oxybutynin 5 mg/d, 7.5 mg/d, 9 mg/d,
10 mg/d, 15 mg/d, 20 mg/d; oxybutynin transdermal system
(TDS) 1.3 mg/d, 2.6 mg/d, 3.9 mg/d; propiverine 20 mg/d,
30 mg/d, 45 mg/d; solifenacin 2.5, 5 mg/d, 10 mg/d, 20 mg/d;
tolterodine 1 mg/d, 2 mg/d, 4 mg/d, 8 mg/d; trospium chloride
40 mg/d, 45 mg/d, 60 mg/d.
Statistical analysis
We aimed to produce a descriptive model allowing us
summarizing data on adverse events statistically. For each of the
7 adverse event categories and each of the treatment arms, the
number of adverse events, weighted according to the grading
provided in Table 1, were added up and divided by the total
number of patients in the corresponding treatment arm. In this
way, the weighted adverse events per patient in each of the trials
given a specific treatment and dosage were determined. The total
score of adverse events was calculated by adding up these estimates
of the 7 adverse event categories.
For all of the 8 adverse event outcomes (7 adverse event
categories and the total score of adverse events), a linear
regression analysis was performed with drug and dosage as
covariates and using a similar concept as Berlin et al. [17] and as
Hasselblad [18], the event outcome for each single treatment
arm as the dependent variable. To preserve randomization
within each trial, we included a dummy variable for each of the
studies. This dummy variable adjusted for differences in risk
profiles and study setup between trials. The drugs were entered
as indicator variables and the dosages were transformed to a
uniform format by giving value 1 to the currently used starting
dosage and the other dosages the multiplication factor as
compared with this dosage. Thus, when the currently used
starting dosage was 7.5 mg/d and dosages of 3.75 mg/d,
7.5 mg/d, 15 mg/d, and 30 mg/d were investigated, these
values were recoded as 0.5, 1, 2, and 4, respectively. Because
every drug has its own specific dose-adverse event relation,
interaction terms between drug and dosage were added.
Furthermore, the analysis was weighted with the total number
of patients in each treatment arm as a substitute for the inverse
of the variance, and the cluster option was used to take into
account that results within one trial will be correlated. We
investigated the influence of several trial characteristics such as
age, gender, and duration of treatment. This was done by
entering them as an interaction term with treatment into the
model. From this regression model we estimated the difference
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between adverse events of the placebo and the dosages applied in
standard clinical practice (i.e. darifenacin 7.5 mg/d, 15 mg/d;
fesoterodine 4 mg/d, 8 mg/d; oxybutynin 10 mg/d, 15 mg/d,
20 mg/d; oxybutynin TDS 3.9 mg/d; propiverine 30 mg/d,
45 mg/d; solifenacin 5 mg/d, 10 mg/d; tolterodine 4 mg/d;
trospium chloride 40 mg/d, 60 mg/d).
All analyses were performed with Stata SE 10.1 (Copyright
1996–2010 StataCorp LP, 4905 Lakeway Drive, College Station,
TX 77845 USA).
Results
We identified 82 reports (Figure S2). Three articles [19–21] not
specifying adverse events, one article [22] not differentiating
adverse events between antimuscarinic and placebo, six articles
[23–28] not discriminating adverse events between different fixed
dosages, and three articles [29–31] only comparing different
releases within the same antimuscarinic and dosage were excluded.
Thus, we finally included 69 trials [32–100] including one report
[66] with two different age strata (Table 2, Data S2). Most trials
had a parallel design (58, 84%) and were placebo-controlled (57,
83%). Overall, the included trials enrolled 26229 patients. The
mean age was 59 years (range 30 to 82), the proportion of women
was 76% (range 0% to 100%) and the mean duration of treatment
was 8 weeks (range 1 to 52 weeks).
We found similar overall adverse event profiles for darifenacin,
fesoterodine, transdermal oxybutynin, propiverine, solifenacin,
tolterodine, and trospium chloride but not for oxybutynin orally
administered when currently used starting dosages were compared
(Figure 1). Orally administered oxybutynin dosages of $10 mg/d
demonstrated the worst adverse event profiles. Darifenacin,
fesoterodine, oxybutynin orally administered, propiverine, and
solifenacin showed a positive and significant dose-adverse event
relation.
Among adverse events, gastrointestinal side effects were most
frequently reported. Only transdermal oxybutynin 3.9 mg/d
showed similar gastrointestinal profiles to placebo (Figure 2).
Ocular/visual adverse events were similar across the various
antimuscarinics when starting dosages were used (Figure S3). This
was also observed for urinary tract related (Figure S4), neurolog-
ical (Figure S5), cardiac (Figure S6), and respiratory tract related
(Figure S7) adverse event profiles. Dermatological adverse events
were insignificant with oral drug administration but a worse profile
was found with transdermal application (Figure S8).
Age, gender, and duration of treatment had no significant
influence on adverse events.
Discussion
Main findings
Our network meta-analysis, which applies a transparent
method, allows direct and indirect comparison of all currently
used antimuscarinics, dosages, formulations and routes of
administration. Moreover, our method provides an easy to grasp
overview of side effects which is important since antimuscarinics
for treating OAB are selected in clinical practice based on the
trade off between drugs’ efficacy and adverse events. The results of
this analysis can be a valuable input for decision analytic models.
Our approach also contributes to a recent call of the GRADE
working group that the strength of evidence should be assessed
considering trade-offs between effect and side effects. Overall
adverse event profiles were similar for all antimuscarinics except
for oxybutynin orally administered when comparing currently
used starting dosages. In addition, except for trospium chloride, we
Table 1. Categorization and grading of adverse events.
Type of adverse events Grading using VAS
Gastrointestinal adverse events
Dry mouth 4
Dry throat 4
Dysgeusia 4
Constipation 4
Diarrhoe 4
Abdominal pain 5
Gastritis 5
Dyspepsia 4
Nausea 5
Vomitus 6
Unspecified gastrointestinal adverse events 5
Ocular/visual adverse events
Dry eye 4
Blurred vision 6
Urinary tract related adverse events
Urinary retention 7
Voiding difficulty 5
Dysuria 5
Urinary tract infection 6
Unspecified urinary tract related adverse events 6
Neurological adverse events
Fatigue 5
Somnolence 8
Sedation 7
Insomnia 6
Confusion 7
Cognitive impairment 7
Depression/lethargy 7
Dizziness/vertigo 5
Headache 5
Cardiac adverse events
Palpitation/tachycardia 5
Hypertension 6
Orthostatic disturbance 6
Fall 8
Respiratory tract related adverse events
Dry nose 3
Cough 4
Nasopharyngitis 4
Sinusitis 4
Upper respiratory tract infection 6
Influenza 6
Dermatological adverse events
Dry skin 2
Erythema/exanthema 4
Pruritus 5
VAS: visual analogue scale (0 =minimum severity, 10 =maximum severity).
doi:10.1371/journal.pone.0016718.t001
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found a positive and significant dose-adverse event relation for the
antimuscarinics.
Findings in the context of existing evidence
In respect to reported adverse events, our data confirm results of
various previous systematic reviews [7–13]. Dry mouth was
consistently the most common complaint [7,8,10,12,13], and this
is in line with our findings that gastrointestinal adverse events were
most frequently reported. In our study, most antimuscarinics had
similar ocular/visual adverse events to placebo when their lower
available dosage was used. This confirms the results of Chapple et
al. [12] regarding blurred vision. Although the inhibitory effect of
antimuscarinics on detrusor muscle contraction could theoretically
cause or aggravate voiding difficulty and urinary retention, urinary
tract related adverse events were not different between anti-
muscarinics and placebo. This is supported by a randomised,
placebo-controlled trial in men with bladder outlet obstruction
showing that antimuscarinic treatment did not adversely affect
urinary function in this high risk group of patients [87]. Central
nervous system (CNS) adverse events are of particular concern as
muscarinic receptors are prominent in the CNS and play an
important role in memory, vigilance, problem solving, stimulus
and response processing [101]. Perry et al. [102] found an
increased occurrence of Alzheimer’s disease (AD) related to a
prolonged antimuscarinic exposure in patients with Parkinson’s
disease raising the concern that chronic antimuscarinic treatment
may increase the risk of AD or accelerate AD pathogenesis.
Notwithstanding the fact that cognitive impairment traditionally
has not been evaluated in antimuscarinics’ trials, CNS adverse
events were rare and we found an overall neurological adverse
event profile for most antimuscarinics similar to placebo in our
study. Cardiac adverse events, particularly the increase of heart
rate and prolongation of the QT interval associated with
polymorphic ventricular tachycardia (or torsade de pointes), can
be serious, and the antimuscarinic agent terodiline was withdrawn
from the market because of an association with QT prolongation
[103]. However, there is no evidence from our data to suggest that
the currently used antimuscarinics increase the risk of cardiac
adverse events when administered at the recommended therapeu-
tic dosages. Respiratory tract related adverse events were
negligible. Dermatological adverse events were insignificant with
oral drug administration but in accordance with previous meta-
analyses [12,13] a worse profile was found with transdermal
application.
Strength and weaknesses
Our network meta-analytic approach provides valuable addi-
tional information to conventional systematic reviews [7–13]. We
performed a joint assessment of all reported adverse events of all
currently prescribed antimuscarinics while by including a dummy
variable, we maintained the comparison of two treatments for
each of the studies. That the overall adverse event profiles of each
antimuscarinic can be summarized in one simple graph (Figure 1)
providing all relevant information at a glance is another strength of
our approach. We believe that this information is useful for health
authorities, policy makers, physicians, and patients alike. As
estimates of the within study variance of the adverse event scores
were not available, a customary network analysis investigating
heterogeneity was not possible. In fact, we assumed heterogeneity
by allowing the outcome parameter to have a variance comprising
the between as well as the within study variance. Eleven studies
used a crossover design. Dependent on the within-subject
correlation, the variance of the within-subject comparison of the
adverse event score will be lower than the between-subject
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comparison [104]. As the weights are inversely proportional with
the variance, this would mean that the weights of the crossover
studies should be increased. We performed a sensitivity analysis
increasing the weights of studies with a crossover design with a
factor two, showing only minimal differences with the presented
results. Although our figures summarize the adverse event profiles
of the antimuscarinics, it is unclear how predictive the mean values
are for an individual patient.
We categorized the antimuscarinics based on the daily dosage
used in clinical practice, but differences in medication frequency
and formulations were not considered. Only for tolterodine a
reasonable number of studies with both immediate and extended
release formulations were available. However, using our meta-
analytic approach, the influence of the release on the occurrence of
adverse events could easily be investigated by entering an
interaction term with treatment into the regression model. Almost
all studies published are fixed dose trials and we excluded the few
studies that did not clearly specify the dose regarding adverse events.
This is an important limitation since in clinical practice the dose of a
drug is often titrated and flexible dose studies tend to report fewer
adverse events. Duration of treatment had no significant influence
on the adverse event profiles but absence of evidence is not evidence
of absence. None of the trials reported whether and how many
patients had two or more adverse events. Therefore, we had to
assume that the occurrence of an adverse event was independent of
the presence of another, although this might be more complex in
clinical reality. Moreover, policy and completeness of adverse event
reporting changed during the last 20 years and differ between the
trials. The impact of this variability on the results is difficult to
determine, but under-reporting of adverse events, particularly in
earlier trials, is likely. It might be argued, that the grading of adverse
events should be based on patients’ opinion, taking into account that
patients’ and physicians’ values and preferences can differ widely
[105]. Basing the grading system on patients’ preferences would
imply an interview in a representative and extensive sample.
However, this would require an additional study that certainly
should be performed to include patients’ grading in this analysis. As
the decision for a specific antimuscarinic treatment is usually taken
by the physician who is supposed to have a deliberate overview of
the manifestations of a specific adverse event, we decided to base
our grading of adverse events on the consensus of 10 independent
experts.
Figure 1. Overall adverse event profiles (from 69 trials) of different antimuscarinic treatments and dosages per day compared with
placebo (reference line through 0). The orange lines represent the currently used starting dosages (oxybutynin 15 mg/d and trospium chloride
60 mg/d may also be used as starting dosages).# mean, 95% confidence interval, TDS transdermal system, VAS visual analogue scale.
doi:10.1371/journal.pone.0016718.g001
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To grade the strength of recommendation, the quality of the
evidence should be assessed. Although only randomized trials are
included (i.e. the highest grade) the quality of evidence should be
downgraded because in most studies the reporting of adverse events
will be imprecise and the probability of reporting bias is presumable.
Implications for research
We believe that our method provides a useful overview of
benefits and downsides of various medications prescribed in a
particular clinical area. To us, the method is of most value for
researchers commissioned to provide comprehensive summaries
and decision-analytic models to guide decisions of health
authorities such as the Centres of Reviews and Disseminations
(CRDs) in the UK or similar institutions in Germany and the
United States of America. We would like to point out that this
approach is equally applicable to the assessment of treatment
effects. From a decision-making point of view there are new
opportunities that could be explored. For example, adding the
patients’ perspective regarding the burden of adverse events and
the minimum expected beneficial effect could be used as
benchmark criteria against which the optimal regimen could be
selected. Finally, data of the form provided in this article are an
ideal starting point for various cost-effectiveness analyses.
Implications for practice
Although antimuscarinics are generally regarded to be well
tolerated, non-adherence to medication represents a major challenge.
In a community setting, up to 40% of patients may discontinue
antimuscarinic treatment due to adverse events [106]. As shown in
previous systematic reviews [7–13], all currently used antimuscarinics
have similar efficacy for the usually prescribed starting dosages (Figure
S1) and this view is also supported by the NICE guideline [107]. Thus,
differences in adverse event profiles should guide the choice for
treatment. We showed that darifenacin 7.5 mg/d, fesoterodine 4 mg/
d, transdermal oxybutynin 3.9 mg/d, propiverine 30 mg/d, solifena-
cin 5 mg/d, tolterodine 4 mg/d, and trospium chloride 40 mg/d (or
60 mg/d) had similar overall adverse event profiles and seem to be
equivalent first choice drugs to start the treatment of OAB. In case
these first choices are ineffective, dose escalation or changing to
another antimuscarinic appears to be reasonable. Oxybutynin dosages
of $10 mg/d are of questionable value in the current treatment of
OAB because of unfavorable adverse event profiles.
Figure 2. Gastrointestinal adverse events profiles (from 69 trials) of different antimuscarinic treatments with currently used
starting dosages per day compared with placebo (reference line through 0). # mean, 95% confidence interval, TDS transdermal system,
VAS visual analogue scale.
doi:10.1371/journal.pone.0016718.g002
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Conclusions
We propose a generally applicable method that summarizes
adverse events in an easy to grasp way using a transparent network
meta-analysis which incorporates all available information from
clinical trials while fully maintaining randomization. Darifenacin
7.5 mg/d, fesoterodine 4 mg/d, transdermal oxybutynin 3.9 mg/
d, propiverine 30 mg/d, solifenacin 5 mg/d, tolterodine 4 mg/d,
and trospium chloride 40 mg/d (or 60 mg/d) seem to be
equivalent first choice drugs to start the treatment of OAB,
whereas oral oxybutynin dosages of $10 mg/d have less favorable
adverse event profiles.
Supporting Information
Figure S1 Efficacy of different antimuscarinics (starting dosages)
compared to placebo (reference line through 0) according to
Chapple et al, Eur Urol 2008;54:543-62 and Staskin et al, Eur
Urol 2009;55:e49-50.
(TIF)
Figure S2 Flow diagram of literature searches and results.
(TIF)
Figure S3 Ocular/visual adverse event profiles (from 45 trials) of
different antimuscarinic treatments with currently used starting
dosages per day compared with placebo (reference line through 0).
# mean, 95% confidence interval, TDS transdermal system, VAS
visual analogue scale.
(TIF)
Figure S4 Urinary tract related adverse event profiles (from 37
trials) of different antimuscarinic treatments with currently used
starting dosages per day compared with placebo (reference line
through 0). # mean, 95% confidence interval, TDS transdermal
system, VAS visual analogue scale.
(TIF)
Figure S5 Neurological adverse event profiles (from 52 trials) of
different antimuscarinic treatments with currently used starting
dosages per day compared with placebo (reference line through 0).
# mean, 95% confidence interval, TDS transdermal system, VAS
visual analogue scale.
(TIF)
Figure S6 Cardiac adverse event profiles (from 22 trials) of
different antimuscarinic treatments with currently used starting
dosages per day compared with placebo (reference line through 0).
# mean, 95% confidence interval, TDS transdermal system, VAS
visual analogue scale.
(TIF)
Figure S7 Respiratory tract related adverse event profiles (from
20 trials) of different antimuscarinic treatments with currently used
starting dosages per day compared with placebo (reference line
through 0). # mean, 95% confidence interval, TDS transdermal
system, VAS visual analogue scale.
(TIF)
Figure S8 Dermatological adverse event profiles (from 21 trials)
of different antimuscarinic treatments with currently used starting
dosages per day compared with placebo (reference line through 0).
# mean, 95% confidence interval, TDS transdermal system, VAS
visual analogue scale.
(TIF)
Data S1 Additional information kindly provided by authors of
eligible trials that reported insufficient data.
(DOC)
Data S2 Database of included trials.
(XLS)
Acknowledgments
The valuable help of Sheila A. Wallace, MSc, Cochrane Incontinence
Review Group, Academic Urology Unit, University of Aberdeen,
Aberdeen, UK, in performing the literature search of this manuscript is
gratefully acknowledged.
Author Contributions
Conceived and designed the experiments: TMK LMB. Per-
formed the experiments: TMK DL MU. Analyzed the data:
TMK LMB CM AGHK. Contributed reagents/materials/analysis
tools: CM AGHK. Wrote the paper: TMK LMB AGHK. Critical revision
of the manuscript for important intellectual content: CM DL
MU HJS.
References
1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thu¨roff J, et al. (2001)
How widespread are the symptoms of an overactive bladder and how
are they managed? A population-based prevalence study. BJU Int 87:
760–766.
2. Abrams P, Kelleher CJ, Kerr LA, Rogers RG (2000) Overactive bladder
significantly affects quality of life. Am J Manag Care 6: S580–590.
3. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, et al.
(2003) Prevalence and burden of overactive bladder in the United States.
World J Urol 20: 327–336.
4. Coyne KS, Margolis MK, Jumadilova Z, Bavendam T, Mueller E, et al. (2007)
Overactive bladder and women’s sexual health: what is the impact? J Sex Med
4: 656–666.
5. Brown JS, Vittinghoff E, Wyman JF, Stone KL, Nevitt MC, et al. (2000)
Urinary incontinence: does it increase risk for falls and fractures?
Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 48:
721–725.
6. Klotz T, Bruggenjurgen B, Burkart M, Resch A (2007) The economic costs of
overactive bladder in Germany. Eur Urol 51: 1654–1662; discussion 1662-
1653.
7. Herbison P, Hay-Smith J, Ellis G, Moore K (2003) Effectiveness of
anticholinergic drugs compared with placebo in the treatment of overactive
bladder: systematic review. BMJ 326: 841–844.
8. Chapple C, Khullar V, Gabriel Z, Dooley JA (2005) The effects of
antimuscarinic treatments in overactive bladder: a systematic review and
meta-analysis. Eur Urol 48: 5–26.
9. Hay-Smith J, Herbison P, Ellis G, Morris A (2005) Which anticholinergic drug
for overactive bladder symptoms in adults. Cochrane Database Syst Rev. pp
CD005429.
10. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic
drugs versus placebo for overactive bladder syndrome in adults. Cochrane
Database Syst Rev: CD003781.
11. Khullar V, Chapple C, Gabriel Z, Dooley JA (2006) The effects of
antimuscarinics on health-related quality of life in overactive bladder: a
systematic review and meta-analysis. Urology 68: 38–48.
12. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, et al. (2008) The
effects of antimuscarinic treatments in overactive bladder: an update of a
systematic review and meta-analysis. Eur Urol 54: 543–562.
13. Novara G, Galfano A, Secco S, D’Elia C, Cavalleri S, et al. (2008) A systematic
review and meta-analysis of randomized controlled trials with antimuscarinic
drugs for overactive bladder. Eur Urol 54: 740–764.
14. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, et al. (2004) Grading
quality of evidence and strength of recommendations. BMJ 328: 1490.
15. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items
for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern
Med 151: 264–269, W264.
16. National Cancer Institute Common Terminology Criteria for Adverse Events
v3.0 (CTCAE). Available: http://ctep.cancer.gov/forms/CTCAEv3.pdf.
17. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI (2002) Individual
patient- versus group-level data meta-regressions for the investigation of treatment
effect modifiers: ecological bias rears its ugly head. Stat Med 21: 371–387.
Adverse Events of Antimuscarinics for Treating OAB
PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e16718
18. Hasselblad V (1998) Meta-analysis of multitreatment studies. Med Decis
Making 18: 37–43.
19. Zeegers AGM, Kiesswetter H, Kramer AEJL, Jonas U (1987) Conservative
therapie of frequency, urgency and urge incontinence: a double-blind clinical
trial of flavoxate hydrochloride, oxybutynin chloride, emepronium bromide
and placebo. World J Urol 5: 57–61.
20. Ju¨nemann KP, Fusgen I (1999) Placebo-controlled, randomised, double-blind,
multicenter clinical trial on the efficacy and tolerability of 1640 mg and
2640 mg trospium chloride (Spasmo-lyt) daily for 3 weeks in patients with urge
incontinence. Neurourol Urodyn 18: 375–376.
21. Gittelman M, Kaufmann J (2003) Solifenacin succinate 10 mg once daily
significantly improves symptoms of overactive bladder. 17th International
Federation of Gynecology and Obstetrics World Congress, Santiago, Chile.
22. Moisey CU, Stephenson TP, Brendler CB (1980) The urodynamic and
subjective results of treatment of detrusor instability with oxybutynin chloride.
Br J Urol 52: 472–475.
23. Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, et al. (1998)
Behavioral vs drug treatment for urge urinary incontinence in older women: a
randomized controlled trial. JAMA 280: 1995–2000.
24. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, et al. (1999) Once
daily controlled versus immediate release oxybutynin chloride for urge urinary
incontinence. OROS Oxybutynin Study Group. J Urol 161: 1809–1812.
25. Versi E, Appell R, Mobley D, Patton W, Saltzstein D (2000) Dry mouth with
conventional and controlled-release oxybutynin in urinary incontinence. The
Ditropan XL Study Group. Obstet Gynecol 95: 718–721.
26. Davila GW, Daugherty CA, Sanders SW (2001) A short-term, multicenter,
randomized double-blind dose titration study of the efficacy and anticholinergic
side effects of transdermal compared to immediate release oral oxybutynin
treatment of patients with urge urinary incontinence. J Urol 166: 140–145.
27. Steers W, Corcos J, Foote J, Kralidis G (2005) An investigation of dose titration
with darifenacin, an M3-selective receptor antagonist. BJU Int 95: 580–586.
28. Chapple C, Dubeau C, Ebinger U, Rekeda L, Viegas A (2007) Darifenacin
treatment of patients ./= 65 years with overactive bladder: results of a
randomized, controlled, 12-week trial. Curr Med Res Opin 23: 2347–2358.
29. Nilsson CG, Lukkari E, Haarala M, Kivela A, Hakonen T, et al. (1997)
Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg
oxybutynin tablet in urge incontinent patients. Neurourol Urodyn 16: 533–542.
30. Birns J, Lukkari E, Malone-Lee JG (2000) A randomized controlled trial
comparing the efficacy of controlled-release oxybutynin tablets (10 mg once
daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose
symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int 85:
793–798.
31. Barkin J, Corcos J, Radomski S, Jammal MP, Miceli PC, et al. (2004) A
randomized, double-blind, parallel-group comparison of controlled- and
immediate-release oxybutynin chloride in urge urinary incontinence. Clin
Ther 26: 1026–1036.
32. Bono AV, Marconi AM, Gianneo E (1982) Oxybutynin for unstable bladder. A
preliminary placebo controlled trial [L’ossibutinina cloridrato nella vescica
instabile pura (Italian)]. Urologia 49: 764–768.
33. Murray KHA, Patterson JR, Stephenson TP (1984) A double-blind three way
cross over placebo controlled trial of cystrin and cetiprin novum. Proceedings of
the 14th annual Meeting of the International Continence Society. 454 p.
34. Riva D, Casolati E (1984) Oxybutynin chloride in the treatment of female
idiopathic bladder instability. Results from double blind treatment. Clin Exp
Obstet Gynecol 11: 37–42.
35. Zorzitto ML, Holliday PJ, Jewett MA, Herschorn S, Fernie GR (1989)
Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-
controlled study. Age Ageing 18: 195–200.
36. Moore KH, Hay DM, Imrie AE, Watson A, Goldstein M (1990) Oxybutynin
hydrochloride (3 mg) in the treatment of women with idiopathic detrusor
instability. Br J Urol 66: 479–485.
37. Takayasu H, Ueno A, Tsutida S, Koiso K, Kurita K, et al. (1990) Clinical
effects of propiverine hydrochloride in the treatment of urinary frequency and
incontinence associated with detrusor overactivity: a double blind, parallel,
placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine)
153: 459–471.
38. Tapp AJ, Cardozo LD, Versi E, Cooper D (1990) The treatment of detrusor
instability in post-menopausal women with oxybutynin chloride: a double blind
placebo controlled study. Br J Obstet Gynaecol 97: 521–526.
39. Sto¨hrer M, Bauer P, Giannetti BM, Richter R, Burgdorfer H, et al. (1991)
Effect of trospium chloride on urodynamic parameters in patients with detrusor
hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled
double-blind trial. Urol Int 47: 138–143.
40. Thu¨roff JW, Bunke B, Ebner A, Faber P, de Geeter P, et al. (1991)
Randomized, double-blind, multicenter trial on treatment of frequency,
urgency and incontinence related to detrusor hyperactivity: oxybutynin versus
propantheline versus placebo. J Urol 145: 813–816; discussion 816-817.
41. Wehnert J, Sage S (1992) Treatment of bladder unstability and urge
incontinence with Propiverine hydrochloride (Mictonormaˆ) and Oxybutynin
chloride (Dridaseaˆ), a randomised crossover study [Therapie der Blaseninst-
abilita¨t und Urge-inkontinenz mit Propiverin hydrochlorid (Mictonormaˆ) und
Oxybutynin chlorid (Dridaseaˆ) - eine randomisierte cross-over-vergleichsstudie
(German)] Aktuel Urol 23: 7–11.
42. Szonyi G, Collas DM, Ding YY, Malone-Lee JG (1995) Oxybutynin with
bladder retraining for detrusor instability in elderly people: a randomized
controlled trial. Age Ageing 24: 287–291.
43. Mazur D, Wehnert J, Dorschner W, Schubert G, Herfurth G, et al. (1995)
Clinical and urodynamic effects of propiverine in patients suffering from
urgency and urge incontinence. A multicentre dose-optimizing study.
Scand J Urol Nephrol 29: 289–294.
44. Abrams P, Jackson S, Mattiasson A, Krishnan K, Haendler L (1996) A
randomised, double-blind, placebo controlled, dose ranging study of the safety
and efficacy of tolterodine in patients with hyperreflexia. Proceedings of the
International Continence Society 26th Annual Meeting. pp 276–277.
45. Jonas U, Hofner K, Madersbacher H, Holmdahl TH (1997) Efficacy and safety
of two doses of tolterodine versus placebo in patients with detrusor overactivity
and symptoms of frequency, urge incontinence, and urgency: urodynamic
evaluation. The International Study Group. World J Urol 15: 144–151.
46. Van Kerrebroeck PE, Serment G, Dreher E (1997) Clinical efficacy and safety
of tolterodine compared to oxybutynin in patients with overactive bladder.
Neurourol Urodyn 16: 478–479. [abstract 491].
47. Abrams P, Freeman R, Anderstrom C, Mattiasson A (1998) Tolterodine, a new
antimuscarinic agent: as effective but better tolerated than oxybutynin in
patients with an overactive bladder. Br J Urol 81: 801–810.
48. Alloussi S, Laval KU, Ballering-Bruhl B, Grobe-Freese M, Bulitta M, et al.
(1998) Trospium chloride (Spasmo-lyt) in patients with motor urge syndrome
(detrusor instability): a double-blind, randomised, multicentre, placebo-
controlled study. Journal of Clinical Research 1: 439–451.
49. Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, et al. (1998) Efficacy
and safety of tolterodine in patients with detrusor instability: a dose-ranging
study. Br J Urol 81: 42–48.
50. Van Kerrebroeck PE, Amarenco G, Thu¨roff JW, Madersbacher HG,
Lock MT, et al. (1998) Dose-ranging study of tolterodine in patients with
detrusor hyperreflexia. Neurourol Urodyn 17: 499–512.
51. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S (1999) Clinical
efficacy and safety of tolterodine compared to oxybutynin and placebo in
patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 10:
283–289.
52. Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K (1999) A placebo-
controlled, multicentre study comparing the tolerability and efficacy of
propiverine and oxybutynin in patients with urgency and urge incontinence.
BJU Int 84: 646–651.
53. Millard R, Tuttle J, Moore K, Susset J, Clarke B, et al. (1999) Clinical efficacy
and safety of tolterodine compared to placebo in detrusor overactivity. J Urol
161: 1551–1555.
54. Sto¨hrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K (1999)
Efficacy and safety of propiverine in SCI-patients suffering from detrusor
hyperreflexia—a double-blind, placebo-controlled clinical trial. Spinal Cord
37: 196–200.
55. Cardozo L, Chapple CR, Toozs-Hobson P, Grosse-Freese M, Bulitta M, et al.
(2000) Efficacy of trospium chloride in patients with detrusor instability: a
placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU
Int 85: 659–664.
56. Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Schubert G, et al.
(2000) Efficacy and cardiac safety of propiverine in elderly patients - a double-
blind, placebo-controlled clinical study. Eur Urol 37: 702–708.
57. Ju¨nemann KP, Al-Shukri S (2000) Efficacy and tolerability of trospium chloride
and tolterodine in 234 patients with urge-syndrome: a double-blind, placebo-
controlled, multicenter clinical trial. Neurourol Urodyn 19: 488–490.
58. Serrano Brambila EA, Quiroga Avila RG, Lorenzo Monterrubio JL, Moreno
Aranda J (2000) Assessment of effectiveness of and tolerance to oxybutynin in
the treatment of unstable bladder in women [Evaluacion de la efectividad y
tolerancia de la oxibutinina en el tratamiento de la vejiga inestable en la mujer
(Spanish)]. Ginecol Obstet Mex 68: 174–181.
59. Jacquetin B, Wyndaele J (2001) Tolterodine reduces the number of urge
incontinence episodes in patients with an overactive bladder. Eur J Obstet
Gynecol Reprod Biol 98: 97–102.
60. Malone-Lee JG, Walsh JB, Maugourd MF (2001) Tolterodine: a safe and
effective treatment for older patients with overactive bladder. J Am Geriatr Soc
49: 700–705.
61. Ulshofer B, Bihr AM, Bodeker RH, Schwantes U, Jahn HP (2001)
Randomised, double-blind, placebo-controlled study on the efficacy and
tolerance of trospium chloride in patients with motor urge incontinence. Clin
Drug Invest 21: 563–569.
62. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A (2001) Tolterodine
once-daily: superior efficacy and tolerability in the treatment of the overactive
bladder. Urology 57: 414–421.
63. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, et al. (2001)
Prospective randomized controlled trial of extended-release oxybutynin
chloride and tolterodine tartrate in the treatment of overactive bladder: results
of the OBJECT Study. Mayo Clin Proc 76: 358–363.
64. Malone-Lee J, Shaffu B, Anand C, Powell C (2001) Tolterodine: superior
tolerability than and comparable efficacy to oxybutynin in individuals 50 years
old or older with overactive bladder: a randomized controlled trial. J Urol 165:
1452–1456.
Adverse Events of Antimuscarinics for Treating OAB
PLoS ONE | www.plosone.org 10 February 2011 | Volume 6 | Issue 2 | e16718
65. Dmochowski RR, Davila GW, Zinner NR, Gittelman MC, Saltzstein DR,
et al. (2002) Efficacy and safety of transdermal oxybutynin in patients with urge
and mixed urinary incontinence. J Urol 168: 580–586.
66. Zinner NR, Mattiasson A, Stanton SL (2002) Efficacy, safety, and tolerability of
extended-release once-daily tolterodine treatment for overactive bladder in
older versus younger patients. J Am Geriatr Soc 50: 799–807.
67. Lee JG, Hong JY, Choo MS, Kwon HY, Chung DY, et al. (2002) Tolterodine:
as effective but better tolerated than oxybutynin in Asian patients with
symptoms of overactive bladder. Int J Urol 9: 247–252.
68. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, et al.
(2003) Comparative efficacy and safety of transdermal oxybutynin and oral
tolterodine versus placebo in previously treated patients with urge and mixed
urinary incontinence. Urology 62: 237–242.
69. Homma Y, Paick JS, Lee JG, Kawabe K (2003) Clinical efficacy and
tolerability of extended-release tolterodine and immediate-release oxybutynin
in Japanese and Korean patients with an overactive bladder: a randomized,
placebo-controlled trial. BJU Int 92: 741–747.
70. Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, et al. (2003)
Prospective, randomized, double-blind study of the efficacy and tolerability of
the extended-release formulations of oxybutynin and tolterodine for overactive
bladder: results of the OPERA trial. Mayo Clin Proc 78: 687–695.
71. Halaska M, Ralph G, Wiedemann A, Primus G, Ballering-Bruhl B, et al. (2003)
Controlled, double-blind, multicentre clinical trial to investigate long-term
tolerability and efficacy of trospium chloride in patients with detrusor
instability. World J Urol 20: 392–399.
72. Cardozo L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I, et al. (2004)
Randomized, double-blind placebo controlled trial of the once daily
antimuscarinic agent solifenacin succinate in patients with overactive bladder.
J Urol 172: 1919–1924.
73. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, et al. (2004)
Solifenacin appears effective and well tolerated in patients with symptomatic
idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase
2 dose-finding study. BJU Int 93: 71–77.
74. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, et al. (2004)
Randomized, double-blind placebo- and tolterodine-controlled trial of the
once-daily antimuscarinic agent solifenacin in patients with symptomatic
overactive bladder. BJU Int 93: 303–310.
75. Haab F, Stewart L, Dwyer P (2004) Darifenacin, an M3 selective receptor
antagonist, is an effective and well-tolerated once-daily treatment for overactive
bladder. Eur Urol 45: 420–429; discussion.
76. Khullar V, Hill S, Laval KU, Schiotz HA, Jonas U, et al. (2004) Treatment of
urge-predominant mixed urinary incontinence with tolterodine extended
release: a randomized, placebo-controlled trial. Urology 64: 269–274;
discussion 274-265.
77. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, et al. (2004) Trospium
chloride improves overactive bladder symptoms: a multicenter phase III trial.
J Urol 171: 2311–2315, quiz 2435.
78. Giannitsas K, Perimenis P, Athanasopoulos A, Gyftopoulos K, Nikiforidis G,
et al. (2004) Comparison of the efficacy of tolterodine and oxybutynin in
different urodynamic severity grades of idiopathic detrusor overactivity. Eur
Urol : - 46: 776–782; discussion 782-773.
79. Abrams P, Kaplan S, Guan Z, Wang J, Roehrborn CG (2005) Efficacy and
safety of tolterodine in a predominantly continent population of male patients
with overactive bladder and nocturia (Abstract). Neurourol Urodyn 24:
495–496.
80. Abrams P, Nordling J, Guan Z, Wang JT, Hussain I (2005) Nighttime dosing of
tolterodine reduces overactive bladder-related nocturnal frequency in patients
with overacitve bladder and nocturia. Eur Urol Suppl 4 3: 62. [abstract 240].
81. Cardozo L, Dixon A (2005) Increased warning time with darifenacin: a new
concept in the management of urinary urgency. J Urol 173: 1214–1218.
82. Nitti V, Wiatrak M, Kreitman L, Lipsitz D (2005) Fesoterodine is an effective
antimuscarinic for patients with overactive bladder (OAB): results of a phase 2
trial. Proceedings of the 35th Annual International Continence Society (ICS):
abstract number 306.
83. Romanzi L, Delconte A, Kralidis G (2005) Impact of darifenacin compared
with tolterodine on incontinence episodes in patients with overactive bladder.
Obstet Gynecol 105: 88.
84. Zinner N, Tuttle J, Marks L (2005) Efficacy and tolerability of darifenacin, a
muscarinic M3 selective receptor antagonist (M3 SRA), compared with
oxybutynin in the treatment of patients with overactive bladder. World J Urol
23: 248–252.
85. Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y, Guvel S, Ozkardes H (2005)
Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective
randomized trial. Br J Clin Pharmacol 59: 588–592.
86. Ju¨nemann KP, Halaska M, Rittstein T, Murtz G, Schnabel F, et al. (2005)
Propiverine versus tolterodine: efficacy and tolerability in patients with
overactive bladder. Eur Urol 48: 478–482.
87. Abrams P, Kaplan S, De Koning Gans HJ, Millard R (2006) Safety and
tolerability of tolterodine for the treatment of overactive bladder in men with
bladder outlet obstruction. J Urol 175: 999–1004; discussion 1004.
88. Abrams P, Cardozo L, Chapple C, Serdarevic D, Hargreaves K, et al. (2006)
Comparison of the efficacy, safety, and tolerability of propiverine and
oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 13:
692–698.
89. Hill S, Khullar V, Wyndaele JJ, Lheritier K (2006) Dose response with
darifenacin, a novel once-daily M3 selective receptor antagonist for the
treatment of overactive bladder: results of a fixed dose study. Int
Urogynecol J Pelvic Floor Dysfunct 17: 239–247.
90. Ju¨nemann KP, Hessdorfer E, Unamba-Oparah I, Berse M, Brunjes R, et al.
(2006) Propiverine hydrochloride immediate and extended release: comparison
of efficacy and tolerability in patients with overactive bladder. Urol Int 77:
334–339.
91. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, et al.
(2006) Tolterodine and tamsulosin for treatment of men with lower urinary
tract symptoms and overactive bladder: a randomized controlled trial. JAMA
296: 2319–2328.
92. Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z (2006) Nighttime dosing
with tolterodine reduces overactive bladder-related nocturnal micturitions in
patients with overactive bladder and nocturia. Urology 67: 731–736; discussion
736.
93. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R (2006) Time to onset
of improvement in symptoms of overactive bladder using antimuscarinic
treatment. BJU Int 97: 540–546.
94. Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, et al. (2006)
Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor
antagonist: an investigation of warning time in patients with OAB. Int J Clin
Pract 60: 119–126.
95. Corcos J, Casey R, Patrick A, Andreou C, Miceli PC, et al. (2006) A double-
blind randomized dose-response study comparing daily doses of 5, 10 and 15
mg controlled-release oxybutynin: balancing efficacy with severity of dry
mouth. BJU Int 97: 520–527.
96. Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT,
et al. (2007) Clinical efficacy, safety, and tolerability of once-daily fesoterodine
in subjects with overactive bladder. Eur Urol 52: 1204–1212.
97. Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, et al. (2007)
Randomized, double-blind, placebo- and propiverine-controlled trial of the
once-daily antimuscarinic agent solifenacin in Japanese patients with overactive
bladder. BJU Int 100: 579–587.
98. Nitti V, Dmochowski R, Sand P, Forst HT, Haag-Molkenteller C, et al. (2007)
Efficacy, safety and tolerability of fesoterodine for overactive bladder
syndrome. J Urol 178: 2488–2494.
99. Staskin D, Sand P, Zinner N, Dmochowski R (2007) Once daily trospium
chloride is effective and well tolerated for the treatment of overactive bladder:
results from a multicenter phase III trial. J Urol 178: 978–983; discussion 983-
974.
100. Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, et al. (2007)
Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and
tolterodine ER 4 mg. Eur Urol 52: 1195–1203.
101. Callaway E, Halliday R, Naylor H (1992) Cholinergic activity and constraints
on information processing. Biol Psychol 33: 1–22.
102. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH (2003) Increased Alzheimer
pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol
54: 235–238.
103. Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med
350: 1013–1022.
104. Curtin F, Altman DG, Elbourne D (2002) Meta-analysis combining parallel
and cross-over clinical trials. I: Continuous outcomes. Stat Med 21: 2131–2144.
105. Kessler TM, Fisch M, Heitz M, Olianas R, Schreiter F (2002) Patient
satisfaction with the outcome of surgery for urethral stricture. J Urol 167:
2507–2511.
106. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A medium-term
analysis of the subjective efficacy of treatment for women with detrusor
instability and low bladder compliance. Br J Obstet Gynaecol 104: 988–993.
107. Urinary incontinence: the management of urinary incontinence in women.
Available: http://www.nice.org.uk/nicemedia/pdf/CG40fullguideline.pdf.
Adverse Events of Antimuscarinics for Treating OAB
PLoS ONE | www.plosone.org 11 February 2011 | Volume 6 | Issue 2 | e16718
